Diagnosis and Management of Pheochromocytoma in Hypertensive Patients

Introduction to Pheochromocytoma

• Pheochromocytoma is a rare cause of hypertension with a prevalence of 0.01% to 0.2% in the general hypertensive population, but may be present in up to 4% of patients with resistant hypertension 1, 2
• These tumors cause hypertension through excessive catecholamine production, which can present as paroxysmal hypertension (episodic) or sustained hypertension (in up to 50% of cases with high norepinephrine production) 1, 3
• Classic symptoms include headache, palpitations, pallor, and sweating ("cold sweat"), which when occurring together have a 90% diagnostic specificity 2, 3
• There is typically a 3-year delay in diagnosis, and approximately one-third of cases are inherited, making early detection crucial 1, 3

Diagnostic Approach

• The American Heart Association recommends measuring plasma free metanephrines or urinary fractionated metanephrines in patients with suspected pheochromocytoma 1, 3
• Plasma free metanephrines have the highest sensitivity (96%-100%) and specificity (89%-98%) for diagnosing pheochromocytoma 1, 3
• Urinary fractionated metanephrines have high sensitivity (86%-97%) and specificity (86%-95%) for diagnosing pheochromocytoma 1, 3
• The European Society of Hypertension recommends clonidine suppression testing in cases of equivocal results with strong clinical suspicion, which has 100% specificity and 96% sensitivity 1, 3, 4

Interpretation of Results and Potential False Positives

• Hypertensive patients may have elevated catecholamine metabolites, especially with obesity 2, obstructive sleep apnea 2, or use of tricyclic antidepressants 1, 3
• False positive elevations are usually <4 times the upper limit of normal 1
• Common antihypertensive medications do not affect plasma free metanephrine measurements when using LC-MS/MS analysis, according to the American College of Cardiology 1, 3

Diagnostic Algorithm

• Initial screening should include measuring plasma free metanephrines or urinary fractionated metanephrines in patients with early-onset hypertension (<30 years) 5, resistant hypertension 5, paroxysmal hypertension with classic symptoms 2, significant blood pressure variability 2, or family history of pheochromocytoma 1
• If results are positive, proceed to imaging if levels are >4 times upper limit of normal 1, 3, or repeat testing and consider clonidine suppression test if levels are moderately elevated (1-4 times upper limit) 1, 4

Importance in Resistant Hypertension

• The American Heart Association recommends considering secondary causes, including pheochromocytoma, in resistant hypertension (BP >140/90 mmHg despite optimal doses of ≥3 antihypertensive medications including a diuretic) 5
• Early diagnosis and treatment can significantly reduce morbidity and mortality associated with pheochromocytoma, according to the European Society of Hypertension 1, 2, 3

Management Approach for Elevated Metanephrines

Initial Assessment

• The management approach for patients with elevated metanephrines should follow a stepwise algorithm based on the degree of elevation, with immediate imaging indicated for levels ≥4 times the upper limit of normal to identify potential pheochromocytoma or paraganglioma 6, 7
• First confirm that interfering agents were avoided prior to testing, as several medications and foods can cause false positive results 6, 7, 8
• Assess the degree of elevation relative to the upper limit of normal reference range 7

Management Algorithm Based on Metanephrine Levels

• For levels ≥4 times the upper limit of normal, results are consistent with pheochromocytoma/paraganglioma and immediate imaging is recommended to localize the lesion 6, 7, 8
• For levels 2-4 times the upper limit of normal, repeat testing in 2 months and consider genetic testing for hereditary syndromes, especially in younger patients 6, 7, 8, 9, 10
• For marginally elevated levels, repeat testing in 6 months and consider clonidine suppression test to exclude false positivity 6, 7

Special Considerations

• For pediatric patients with suspected hereditary syndromes, begin surveillance at age 6-8 years for HPP (hereditary paraganglioma/pheochromocytoma) syndromes 6, 7
• For pediatric patients with suspected von Hippel-Lindau syndrome, begin surveillance at age 2 years 9, 11

Follow-up After Initial Management

• For confirmed pheochromocytoma/paraganglioma, refer for surgical evaluation 12
• For patients with genetic syndromes, implement appropriate long-term surveillance protocols 8, 9, 10
• For patients with negative imaging but persistent biochemical abnormalities, consider annual biochemical testing and periodic reimaging 7

Diagnostic Approach for Pheochromocytoma and Paraganglioma

Diagnostic Testing

• Urine fractionated metanephrines are considered an acceptable alternative to plasma testing for diagnosing pheochromocytoma and paraganglioma, with high sensitivity (86-97%) and specificity (86-95%), and may be preferred for testing low-risk patients or pediatric patients who are not yet continent of urine 13, 14
• Plasma free metanephrines should ideally be collected from an indwelling venous catheter, after the patient has been lying supine for 30 minutes, to limit false positive results 13, 14
• For pediatric patients with suspected hereditary syndromes, surveillance with plasma metanephrines should begin at age 2 years for von Hippel-Lindau syndrome 13, 14

Special Populations

• Urine fractionated metanephrines may be a more practical option for pediatric patients once they are continent of urine 13, 14
• Plasma free metanephrines can help predict tumor size, location, presence of metastases, and underlying genetic mutations in high-risk patients with familial endocrine syndromes 13, 14

Diagnosing Pheochromocytoma with Biochemical Tests

Biochemical Testing

• If plasma testing is equivocal (less than fourfold elevation), a follow-up 24-hour urine collection for catecholamines and metanephrines should be performed, as recommended by the American Society of Clinical Oncology, with high sensitivity and specificity 15, 16
• Plasma methoxytyramine measurement can help assess the likelihood of malignant disease, with a high degree of accuracy, according to the European Society for Medical Oncology 16
• For patients with suspected metastatic disease, functional imaging may be indicated, as suggested by the National Comprehensive Cancer Network, to confirm the presence of metastases 16, 17

Diagnostic and Management Approach for Pheochromocytoma

Imaging Studies

• MRI is preferred for suspected pheochromocytoma due to risk of hypertensive crisis with IV contrast for CT, and for patients with established pheochromocytoma, FDG-PET appears superior to MIBG for detecting malignant tumors, particularly in patients with SDHB mutation 18
• Fine needle biopsy of suspected pheochromocytoma is contraindicated due to risk of hypertensive crisis 18

Genetic Considerations

• SDHB mutations are associated with higher risk of aggressive behavior and metastatic disease 19

Follow-up Protocol

• Patients with SDHB mutations require more intensive surveillance due to higher risk of malignancy 19

Pitfalls and Caveats

• A PASS (Pheochromocytoma of the Adrenal gland Scaled Score) score of ≥4, a large primary tumor, and/or a mutation in the SDHB gene should alert the clinician to carry out extended and prolonged (life-long) monitoring 19

Diagnostic Testing for Pheochromocytoma

Biochemical Testing and Imaging

• The European Society of Cardiology recommends clonidine suppression testing in cases of equivocal results with strong clinical suspicion, with 100% specificity and 96% sensitivity 20
• If initial imaging is negative but biochemical evidence is positive, extend imaging to include chest and neck, and consider functional imaging, as suggested by the European Journal of Nuclear Medicine and Molecular Imaging 21
• Avoid fine needle biopsy of suspected pheochromocytoma as it is contraindicated due to risk of hypertensive crisis, according to the European Journal of Nuclear Medicine and Molecular Imaging 22

Doxazosin Use in Pheochromocytoma Patients

Clinical Context for Doxazosin Use

• Doxazosin is an alpha-1 selective blocker commonly used in the preoperative management of pheochromocytoma patients, typically started 7-14 days before surgery with gradually increasing dosages until blood pressure targets are achieved 23

Important Caveats About Drug Interference

• Several other foods and medications may interfere with metanephrine analysis and should be avoided prior to testing, but alpha-1 selective blockers like doxazosin are not among them 24

Practical Testing Recommendations

• Confirm that interfering agents (excluding doxazosin) were avoided prior to testing 24
• For plasma free metanephrines, ideally collect from an indwelling venous catheter after the patient has been lying supine for 30 minutes to limit false positive results 24

Pheochromocytoma Diagnosis and Management

Preoperative Preparation

• The Endocrine Society recommends that if surgery is planned before pheochromocytoma is definitively excluded, alpha-adrenoceptor blockade must be used preoperatively, with a threshold of ≥2-fold elevation of normetanephrine with hyperadrenergic symptoms, and alpha-blockade should be started 7-14 days preoperatively with gradually increasing dosages until blood pressure targets are achieved 25
• Assessment for hyperadrenergic symptoms, such as sustained or intermittent palpitations, tachycardia, diaphoresis, tremors, or new-onset hypertension, is crucial in patients with borderline elevated metanephrines, as recommended by the Endocrine Society 25

Diagnosis and Management of Pheochromocytoma

Initial Biochemical Testing

• The European Society of Endocrinology recommends measuring plasma-free metanephrines as the first-line diagnostic test for pheochromocytoma, as this provides the highest sensitivity (99%) and negative predictive value, reliably excluding the tumor when normal 26, 27
• All patients with suspected pheochromocytoma must undergo biochemical confirmation before any intervention, as unrecognized tumors can cause life-threatening hypertensive crises 26, 27

Additional Biomarkers

• The European Society of Endocrinology recommends measuring plasma methoxytyramine when available, as elevated levels indicate higher malignancy risk 26, 27, 28

Clinical Context for Testing

• Adrenal incidentaloma must systematically rule out pheochromocytoma before any biopsy or intervention, according to the European Society of Endocrinology 26, 27
• Never perform fine needle biopsy of a suspected pheochromocytoma before biochemical exclusion, as this can precipitate fatal hypertensive crisis, as stated by the American College of Clinical Endocrinologists 28, 29

Imaging Localization

• Only proceed to imaging after biochemical confirmation, as recommended by the European Society of Endocrinology 26, 27
• Obtain cross-sectional imaging of chest, abdomen, and pelvis to detect metastases, according to the American College of Radiology 26, 29

Functional Imaging Indications

• Consider functional imaging when any of the following high-risk features are present, such as tumor size ≥5 cm, extra-adrenal paraganglioma, SDHB germline mutation, or plasma methoxytyramine >3-fold above upper limit, as recommended by the European Society of Endocrinology 28, 29

Genetic Testing

• Extra-adrenal tumors and bilateral adrenal tumors are indications for genetic testing, according to the American College of Medical Genetics 27, 29

Post-Surgical Follow-Up

• All patients require long-term surveillance due to risk of malignant recurrence, particularly those with SDHB mutations, extra-adrenal tumors, or tumors >5 cm, as stated by the American College of Clinical Endocrinologists 29
• Repeat biochemical testing 14 days post-surgery to confirm complete resection, and follow-up every 3-4 months for 2-3 years, then every 6 months, as recommended by the European Society of Endocrinology 29

Plasma Free Metanephrines Collection Guidelines

Collection Method Recommendations

• The American College of Cardiology recommends that plasma free metanephrines should ideally be collected from an indwelling venous catheter after the patient has been lying supine for 30 minutes to limit false positive results 30
• Clinicians may elect to bypass the ideal collection approach, but marginally elevated results should prompt repetition of testing under ideal conditions 30
• Initial screening in high-risk populations, such as patients with hereditary syndromes, should use an indwelling catheter with 30 minutes supine rest to minimize false positives 30
• Follow-up testing for marginally elevated results should also use an indwelling catheter with 30 minutes supine rest 30

Interpretation and Testing

• If levels are >4 times upper limit of normal, proceed directly to imaging to localize the lesion, as this degree of elevation is consistent with pheochromocytoma regardless of collection method 30
• If levels are 2-4 times upper limit of normal, repeat testing in 2 months, ideally using an indwelling catheter with proper positioning 30
• If marginally elevated (1-2 times upper limit), repeat testing in 6 months using an indwelling catheter after 30 minutes supine rest, or consider clonidine suppression test 30
• Confirm that interfering medications and foods were avoided prior to testing, as several agents can cause false elevations 30
• Never proceed to imaging without biochemical confirmation first, as unrecognized pheochromocytomas can cause life-threatening hypertensive crises during procedures 30

Evaluation of Hypertension with Suspected Pheochromocytoma

Clinical Presentation and Screening

• The American College of Cardiology recommends checking catecholamines (plasma free metanephrines or 24-hour urinary fractionated metanephrines) to screen for pheochromocytoma in patients with hypertension and episodic palpitations and headache, as this combination represents a classic presentation that warrants immediate biochemical testing 31, 32, 33
• The triad of headache, palpitations, and sweating in a hypertensive patient has 93.8% specificity and 90.9% sensitivity for pheochromocytoma, with an exclusion value of 99.9% when absent 31, 33
• Episodic symptoms (palpitations and headache) despite treatment initiation are key clinical indicators for pheochromocytoma screening 31, 33

Diagnostic Approach

• First-line biochemical testing should include plasma free metanephrines (highest sensitivity 96-100%, specificity 89-98%) or 24-hour urinary fractionated metanephrines (sensitivity 86-97%, specificity 86-95%) 31, 33, 34
• The clonidine suppression test has 100% specificity and 96% sensitivity for pheochromocytoma diagnosis 35

Management and Pitfalls

• The American College of Cardiology recommends against initiating beta-blockade alone in a patient with suspected pheochromocytoma before alpha-blockade, as this can precipitate severe hypertensive crisis due to unopposed alpha-adrenergic stimulation 36
• Procedures or medications that can trigger catecholamine release should be avoided until pheochromocytoma is excluded, including contrast-enhanced CT (use MRI preferentially), fine needle biopsy of adrenal masses, and certain medications 31

Additional Evaluation

• The American College of Cardiology recommends completing standard hypertension evaluation while pursuing pheochromocytoma workup, including serum electrolytes, serum creatinine with eGFR, fasting glucose or HbA1c, lipid profile, ECG for left ventricular hypertrophy, and urinalysis with albumin/creatinine ratio 31, 32
• The presence of unprovoked hypokalemia would shift suspicion toward primary aldosteronism, requiring aldosterone/renin ratio testing 31, 32, 33

Pheochromocytoma and Paraganglioma Diagnosis and Management

Biochemical Testing and Imaging

• For suspected head/neck paragangliomas, perform MRI with angiography sequences to assess multifocality and tumor extension, as recommended by The Lancet Diabetes and Endocrinology 37
• Obtain whole-body anatomic imaging together with PET (preferably with radiolabeled somatostatin analogs) for suspected pheochromocytoma/paraganglioma, according to The Lancet Diabetes and Endocrinology 37
• Up to 30% of head/neck paragangliomas produce dopamine, indicated by increases in plasma methoxytyramine, as reported by The Lancet Diabetes and Endocrinology 37
• Urine methoxytyramine is not useful as it derives from renal DOPA decarboxylation, not tumor production, as stated by The Lancet Diabetes and Endocrinology 37
• Patients with plasma normetanephrine levels more than double the upper reference limit are rare (2.3%) in head/neck paragangliomas and suggest extra-cranial disease, according to The Lancet Diabetes and Endocrinology 37
• For head/neck paragangliomas, MRI with angiography (sensitivity 88.7%, specificity 93.7%) is first-line, as recommended by The Lancet Diabetes and Endocrinology 37
• Temporal bone CT provides essential information on bone involvement for skull base paragangliomas, as reported by The Lancet Diabetes and Endocrinology 37
• Whole-body PET with radiolabeled somatostatin analogs is preferred for SDHD-related tumors, according to The Lancet Diabetes and Endocrinology 37
• SDHD pathogenic variants show autosomal dominant transmission and require specialized surveillance, as stated by The Lancet Diabetes and Endocrinology 37
• Consider referral to specialized centers with experience in these rare tumors, as recommended by The Lancet Diabetes and Endocrinology 37

Pheochromocytoma Diagnosis and Management

Diagnostic Approach

• If plasma free metanephrines levels are equivocal, a 24-hour urine collection for fractionated metanephrines and catecholamines should be performed, as recommended by the Genetics in Medicine guidelines 38
• Alpha-blockade must be started 7-14 days preoperatively if pheochromocytoma is confirmed, according to the Genetics in Medicine guidelines 38

Preoperative Management

• The American College of Cardiology recommends that alpha-blockade should be initiated 7-14 days before surgery to prevent hypertensive crisis, as supported by the Genetics in Medicine guidelines 38

Clonidine Suppression Test for Pheochromocytoma Diagnosis

Introduction to Diagnostic Testing

• The European Society of Hypertension and American Heart Association recommend the clonidine suppression test for equivocal biochemical results with strong clinical suspicion of pheochromocytoma, as it has a high specificity and sensitivity for distinguishing true pheochromocytoma from false positive results 39

Diagnostic Procedures

• Functional imaging with MIBG is reserved for confirmed pheochromocytoma cases to detect metastatic disease or when anatomical imaging is negative despite positive biochemistry, according to the Annals of Oncology 39
• Adrenal biopsy of suspected pheochromocytoma is absolutely contraindicated due to the risk of precipitating fatal hypertensive crisis, as stated in the Annals of Oncology 39
• Contrast-enhanced CT or any invasive procedures should not be performed until pheochromocytoma is definitively excluded, as these can trigger catecholamine crisis, according to the Annals of Oncology 39

Pheochromocytoma Diagnosis and Management

Clinical Presentation and Diagnostic Approach

• Life-threatening complications can occur, including syncope, cardiac arrest, myocardial infarction, cardiomyopathy, hypertensive crisis, stroke, or sudden death, in patients with pheochromocytoma 40, 41
• Head and neck paragangliomas (parasympathetic origin) typically do not produce catecholamines and present with mass effect symptoms, such as hearing loss, pulsatile tinnitus, cough, hoarseness, dysphagia, facial palsy, pain, or abnormal tongue motility 40, 41

High-Risk Populations and Genetic Testing

• Family history of pheochromocytoma or hereditary syndromes (MEN2, VHL, NF1, SDHx mutations) is an indication for screening 40
• Approximately 30-35% of pheochromocytomas are hereditary with autosomal dominant inheritance 40, 41
• SDHB mutations are associated with higher malignancy risk and require more intensive lifelong surveillance 40, 41
• SDHD mutations show maternal imprinting—only paternal inheritance causes disease 40, 41

Diagnostic Approach to Pheochromocytoma

Biochemical Testing and Imaging

• For patients with strong clinical suspicion of pheochromocytoma and less than fourfold elevation in plasma testing, a 24-hour urine collection for fractionated metanephrines and catecholamines is recommended, as suggested by the Genetics in Medicine guideline 42
• Functional imaging with MIBG or FDOPA-PET is indicated for high-risk features: tumor size ≥5 cm, extra-adrenal paraganglioma, SDHB germline mutation, or plasma methoxytyramine >3-fold above upper limit, according to the Genetics in Medicine guideline 42
• Hypertensive patients with a family history of pheochromocytoma or hereditary syndromes (MEN2, VHL, NF1, SDHx mutations) should be screened for pheochromocytoma, and those with NF1 over 30 years of age, pregnant, or with paroxysmal hypertension should also be screened, as recommended by the Genetics in Medicine guideline 42

Clonidine Suppression Test in Pheochromocytoma Diagnosis

Introduction to Clonidine Suppression Test

• The European Society of Hypertension recommends the clonidine suppression test for patients with equivocal biochemical results (plasma metanephrines 1-4 times the upper limit of normal) when clinical suspicion remains high, as it has 96-100% sensitivity and 100% specificity for distinguishing true pheochromocytoma from false-positive elevations 43

Diagnostic Algorithm

• The American Heart Association and European Society of Hypertension suggest using the clonidine suppression test when plasma free metanephrines are marginally elevated (1-2 times upper limit of normal) with strong clinical suspicion (classic triad of headache, palpitations, sweating) 44
• The European Society of Hypertension recommends repeating testing in 2 months and considering genetic testing for patients with plasma metanephrines 2-4 times upper limit of normal 44
• For patients with marginally elevated plasma metanephrines (1-2 times upper limit of normal), the European Society of Hypertension suggests repeating the test in 6 months or performing the clonidine suppression test if clinical suspicion is high 44

Test Interpretation and Clinical Context

• The European Society of Hypertension states that very high baseline metanephrine values require no further pharmacological testing, and the clonidine test is specifically recommended when plasma or urine values are only modestly elevated, despite a strong clinical suspicion 43
• The European Society of Hypertension emphasizes that the clonidine suppression test should never replace initial biochemical screening or be used when diagnosis is already clear from markedly elevated metanephrines 43

Historical Indicators for Suspected Pheochromocytoma

Classic Catecholamine‑Excess Symptoms

Hereditary and Family‑History Factors

Mass‑Effect Symptoms of Extra‑Adrenal Paragangliomas

Age‑Related Presentation

SDHB‑Associated Malignancy Risk

Imaging and Surveillance Guidelines for Pheochromocytoma and Paraganglioma

Preferred Anatomical Imaging

• Magnetic resonance imaging (MRI) is the preferred first‑line modality for suspected pheochromocytoma because the use of intravenous contrast in computed tomography (CT) can precipitate hypertensive crises. 47
• If biochemical testing has definitively excluded pheochromocytoma, contrast‑enhanced CT is an acceptable alternative and is less costly than MRI. 47

Functional Imaging Indications

• Extra‑adrenal tumor location (paraganglioma) warrants functional imaging to improve lesion detection. 48
• In patients with confirmed pheochromocytoma, ^18F‑FDG PET is superior to ^123I‑MIBG scintigraphy for identifying malignant disease, especially in carriers of SDHB germline mutations. 47

Procedural Safety

• Fine‑needle biopsy of a lesion suspected to be pheochromocytoma is absolutely contraindicated because it can trigger a fatal hypertensive crisis. 47

Surveillance of High‑Risk Genetic Carriers

• Individuals with SDHB germline mutations should undergo more intensive, lifelong surveillance due to a markedly higher risk of aggressive and metastatic disease. 47

Extended Monitoring Criteria (Post‑Treatment)

All three extended‑monitoring criteria are supported by evidence from both the Annals of Oncology (2012) and the European Journal of Nuclear Medicine and Molecular Imaging (2012).* 47, 48

Diagnostic Imaging, Biomarkers, and Procedural Safety in Pheochromocytoma

Biochemical Markers

• Plasma metanephrine measurement provides prognostic information regarding the risk of malignancy in pheochromocytoma (based on evidence from Annals of Oncology, 2012) 49

Anatomical Imaging

• Magnetic resonance imaging (MRI) is the preferred first‑line modality for locating suspected pheochromocytoma, because iodinated contrast used in computed tomography (CT) can precipitate a hypertensive crisis (Annals of Oncology, 2012) 49
• CT should only be employed after biochemical tests have definitively excluded pheochromocytoma (Annals of Oncology, 2012) 50

Functional Imaging

• 18F‑FDG PET imaging outperforms ¹²³I‑MIBG scintigraphy for detecting malignant pheochromocytoma, particularly in patients harboring SDHB mutations (Annals of Oncology, 2012) 49

Genetic Risk

• Germline SDHB mutations are linked to a markedly higher risk of malignant pheochromocytoma and therefore mandate lifelong surveillance (Annals of Oncology, 2012) 49

Procedural Contraindications and Safety

• Fine‑needle aspiration biopsy of a suspected pheochromocytoma is absolutely contraindicated because it can trigger a fatal hypertensive crisis (Annals of Oncology, 2012) 49
• Imaging or invasive procedures must not be performed before biochemical confirmation of pheochromocytoma, as unrecognized tumors can cause life‑threatening hypertensive crises (Annals of Oncology, 2012) 50

High‑Risk Genetic Features and Multidisciplinary Management of Suspected Pheochromocytoma

Genetic Risk Factors

• Germline SDHB mutations confer up to a 70 % risk of metastatic pheochromocytoma/paraganglioma and therefore mandate immediate referral to an endocrinology or hypertension specialist for intensive surveillance and management. 51, 52, 53, 54, 55

Multidisciplinary Care

• All patients with suspected or confirmed pheochromocytoma should be presented at a multidisciplinary expert team meeting—including endocrinology, surgery, anesthesiology, and radiology—at the time of initial diagnosis to coordinate imaging, biochemical confirmation, genetic testing, and pre‑operative planning. 51, 52, 53, 54, 55